METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced prostate cancer patients in major drug trial
Disease control Recruiting nowThis study is testing whether a new drug called opevesostat works better than two standard treatments (abiraterone or enzalutamide) for men with advanced prostate cancer that has spread and stopped responding to prior hormone therapy. The main goal is to see if opevesostat can ke…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New pill targets immune system to fight tough cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-1607 in adults with advanced cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, both alone and combined with a common chemot…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
Personalized immune cells target advanced prostate cancer in new trial
Disease control Recruiting nowThis trial is testing whether modified immune cells can help control advanced prostate cancer that has stopped responding to standard hormone treatments. Doctors take a patient's own immune cells, modify them to recognize prostate cancer proteins, and infuse them back into the bo…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Gut bacteria targeted in fight against advanced prostate cancer
Disease control Recruiting nowThis early-stage trial is testing whether a combination of common antibiotics can change the gut bacteria (microbiome) to help a prostate cancer drug work better. It is for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy and ch…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Pronged attack on advanced cancers enters human testing
Disease control Recruiting nowThis study is testing a new experimental drug called REGN5678, which is designed to help the body's immune system find and attack cancer cells. It is being tested alone and in combination with an existing immunotherapy drug (cemiplimab) in patients with advanced prostate cancer o…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial offers hope for men with aggressive prostate cancer
Disease control Recruiting nowThis is the first study in people testing a new drug called KTX2001 for advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give the drug alone and combined with an existing medication (darolutamide) to about 144 men to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Cancer drug tested for safety in patients with weakened kidneys
Disease control Recruiting nowThis study aims to understand if a prostate cancer drug called lutetium vipivotide tetraxetan is safe for men whose kidneys don't work well. Researchers will measure how much radiation the drug delivers to organs and track side effects in 20 men with advanced prostate cancer who …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Scientists test if more doses of cancer vaccine can sharpen Body's defenses
Disease control Recruiting nowThis small, early-stage study is testing whether giving more doses of an existing prostate cancer immunotherapy, called Sipuleucel-T, can create a stronger immune response against the cancer. It will involve about 13 men with advanced prostate cancer that has spread and stopped r…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Natural supplements join fight against tough prostate cancer
Disease control Recruiting nowThis study is testing if adding green tea extract and quercetin supplements to standard chemotherapy (docetaxel) helps men with advanced prostate cancer that has stopped responding to hormone therapy. Researchers will compare the combination to a placebo plus chemotherapy to see …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Charles Drew University of Medicine and Science • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New cancer drug combo trial seeks to control advanced tumors
Disease control Recruiting nowThis study is testing a new drug called XL092, both by itself and in combination with other immunotherapy drugs, for people with advanced solid tumors that cannot be removed by surgery. The main goals are to find safe doses and see if the treatments can shrink tumors or slow thei…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New hope for men battling Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new oral medicine called mevrometostat, alone and combined with an existing drug (enzalutamide), for men with advanced prostate cancer that has worsened despite prior treatment. The main goals are to find a safe dose and see if the treatment can help contr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC